---
title: "Inovio Pharmaceuticals Announces New Equity Financing Agreement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294508472.md"
description: "Inovio Pharmaceuticals announced a $18.3 million equity financing deal with Piper Sandler, involving the sale of common shares and warrants closing July 31, 2026. This capital raise supports its DNA medicine pipeline but may dilute shareholders. Analysts maintain a 'Hold' rating with a $2.50 target, while AI analysis rates INO as Neutral due to weak financials despite promising clinical data for INO-3107."
datetime: "2026-07-31T11:48:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294508472.md)
  - [en](https://longbridge.com/en/news/294508472.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294508472.md)
---

# Inovio Pharmaceuticals Announces New Equity Financing Agreement

Inovio Pharmaceuticals ( (INO) ) has shared an announcement.

On July 29, 2026, Inovio Pharmaceuticals entered an underwriting agreement with Piper Sandler for a public offering of 21,052,632 common shares and accompanying warrants, plus additional warrants via an exercised 30-day option. The structure, which includes pre-funded warrants and ownership caps, is expected to generate about $18.3 million in net proceeds, with closing targeted for July 31, 2026.

Each warrant will be immediately exercisable for two shares at $1.10 and will remain outstanding for five years, with limits designed to prevent individual holders from exceeding specified ownership thresholds. The deal, made off an effective shelf registration, underscores Inovio’s continuing reliance on equity-linked financing to fund its DNA medicines pipeline, potentially diluting existing shareholders while bolstering the company’s capital position.

The most recent analyst rating on (INO) stock is a Hold  
with a $2.50 price target.  
To see the full list of analyst forecasts on Inovio Pharmaceuticals stock,  
see the INO Stock Forecast page.

**Spark’s Take on INO Stock**

According to Spark, TipRanks’ AI Analyst, INO is a Neutral.

The score is constrained primarily by very weak financial performance (minimal revenue, persistent losses, and ongoing cash burn with rising balance-sheet risk) and bearish technical trends. Offsetting these, the latest earnings call highlighted meaningful regulatory progress and encouraging clinical data for INO-3107, though near-term financing and regulatory uncertainties remain significant.

To see Spark’s full report on INO stock,  
click here.

**More about Inovio Pharmaceuticals**

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing DNA medicines targeting HPV-related diseases, cancer and infectious diseases. The company’s platform is designed to optimize the design and delivery of DNA-based therapeutics that train the body to generate its own disease-fighting mechanisms.

Headquartered in Plymouth Meeting, Pa., Inovio operates in the competitive biopharmaceutical sector with a particular emphasis on immunotherapies and prophylactic treatments. Its work in DNA medicines positions the firm within a niche of next-generation genetic therapies aimed at both treatment and prevention across multiple indications.

**Average Trading Volume:** 2,874,399

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $85.56M

Find detailed analytics on INO stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [INO.US](https://longbridge.com/en/quote/INO.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)

## Related News & Research

- [Inovio Pharmaceuticals (NASDAQ:INO) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS](https://longbridge.com/en/news/295718213.md)
- [Inovio publishes Q2 2026 financial results presentation focusing on INO-3107 BLA review progress](https://longbridge.com/en/news/295713543.md)
- [INO: INO-3107 nears FDA decision as net loss drops 74% and pipeline advances with strong cash reserves](https://longbridge.com/en/news/295713447.md)
- [Scott Galloway says GLP-1 drugs are a 'silver bullet' for America's woes, if we're not 'stupid enough' to get in the way](https://longbridge.com/en/news/295999435.md)
- [DNA X delays Q2 10-Q filing, cites convertible debt and consolidation accounting complexities](https://longbridge.com/en/news/295970722.md)